Otero Jose Manuel sold $6K of LXEO

Otero Jose Manuel (Chief Operating Officer) sold 1,304 shares of Lexeo Therapeutics, Inc. (LXEO) at $4.96 on 2026-08-18.

Original reporting
SEC EDGAR · Otero Jose Manuel
Published Aug 19, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LXEO
Neutral
high confidence
Mentioned
$LXEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LXEONeutralLow
01

Why it matters

The sale represents a modest reduction in insider stake, unlikely to affect market perception.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: post-market 2026-08-18

Background

Form 4 filings disclose insider trades; investors monitor for material changes.

Company-level read

Ticker impact

$LXEONeutralHigh confidence
Context

COO Jose Manuel Otero sold 1,304 shares for $6,464, a routine insider sale disclosed via Form 4.

Expected impact

No material impact on LXEO stock price.

Evidence & confidence

The transaction size is small relative to total holdings and market cap; typical for insiders.

Market effects

None; isolated insider transaction.

None.

None.

Counterpoint

Even small insider sales can signal lack of confidence, but context suggests routine liquidity.

Key entities

  • Lexeo Therapeutics, Inc.

    Biotech firm listed on NASDAQ under LXEO.

  • Jose Manuel Otero

    Chief Operating Officer of Lexeo Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LXEOMedAI 8/10

Lexeo Therapeutics Stock Jumps 12% On Positive Gene Therapy Data

Lexeo Therapeutics (LXEO) stock rose 12% after positive interim results from its Phase I/II HEROIC-PKP2 study of LX2020, a gene therapy for PKP2 arrhythmogenic cardiomyopathy. The therapy reduced non-sustained ventricular tachycardia by 80% and premature ventricular contractions by 44% in high-dose patients. The company reported a Q3 net loss of $38.3 million, up from $20.3 million last year, with R&D expenses increasing to $34.5 million.

$LXEOHighAI 9/10

Why is Lexeo Therapeutics stock surging today?

Lexeo Therapeutics (LXEO) stock rose 23.7% in pre-market trading after reporting positive interim data from its HEROIC-PKP2 trial for LX2020, showing 80% reduction in NSVT. The FDA indicated openness to using NSVT as a surrogate endpoint. Analysts raised price targets, with Raymond James increasing to $42. The company reported $219.1M in cash, funding operations into 2028, despite a Q3 net loss of $38.3M.